We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
-4.22%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$16.9B
AUM Growth
-$2.13B
(-11%)
Cap. Flow
-$1.02B
Cap. Flow
% of AUM
-6.06%
Top 10 Holdings %
Top 10 Hldgs %
39.23%
Holding
1,372
New
74
Increased
459
Reduced
680
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$138M |
| 2 |
NVIDIA
NVDA
|
+$69.6M |
| 3 |
Synaptics
SYNA
|
+$37.7M |
| 4 |
Microchip Technology
MCHP
|
+$29.7M |
| 5 |
Lam Research
LRCX
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$184M |
| 2 |
iShares China Large-Cap ETF
FXI
|
+$170M |
| 3 |
XLNX
Xilinx Inc
XLNX
|
+$169M |
| 4 |
Apple
AAPL
|
+$131M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$110M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.16% |
| 2 | Financials | 15.03% |
| 3 | Energy | 6.15% |
| 4 | Healthcare | 5.33% |
| 5 | Consumer Discretionary | 2.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Bank OZK
OZK
$5.72B
| $5.75M | 0.03% |
134,622
+7,982
| +6% | +$372K |
|
352
Enphase Energy
ENPH
$5.49B
| $5.71M | 0.03% |
28,287
-4,911
| -15% | -$772K |
|
353
Insmed
INSM
$21.4B
| $5.67M | 0.03% |
241,500
+41,683
| +21% | +$968K |
|
354
Denali Therapeutics
DNLI
$3.83B
| $5.66M | 0.03% |
175,962
+54,207
| +45% | +$1.87M |
|
|
Y
355
DELISTED
Alleghany Corp
Y
| $5.66M | 0.03% |
6,682
-330
| -5% | -$229K |
|
|
CCXI
356
DELISTED
ChemoCentryx, Inc.
CCXI
| $5.65M | 0.03% |
225,404
+68,183
| +43% | +$1.92M |
|
357
Opko Health
OPK
$970M
| $5.64M | 0.03% |
1,639,109
+752,379
| +85% | +$2.66M |
|
358
Neurocrine Biosciences
NBIX
$17B
| $5.62M | 0.03% |
59,896
-6,304
| -10% | -$534K |
|
359
Zentalis Pharmaceuticals
ZNTL
$345M
| $5.59M | 0.03% |
121,170
+55,971
| +86% | +$3.02M |
|
360
Acadia Pharmaceuticals
ACAD
$4.51B
| $5.59M | 0.03% |
230,683
-6,215
| -3% | -$150K |
|
|
HZNP
361
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.58M | 0.03% |
53,064
+650
| +1% | +$63.3K |
|
362
Natera
NTRA
$39.3B
| $5.58M | 0.03% |
137,187
+78,208
| +133% | +$4.7M |
|
|
FOLD
363
DELISTED
Amicus Therapeutics
FOLD
| $5.57M | 0.03% |
588,584
+63,739
| +12% | +$598K |
|
364
NetApp
NTAP
$38.2B
| $5.57M | 0.03% |
67,062
-10,273
| -13% | -$893K |
|
365
United Therapeutics
UTHR
$21.9B
| $5.55M | 0.03% |
30,910
+2,946
| +11% | +$561K |
|
|
ISEE
366
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.49M | 0.03% |
326,314
-35,115
| -10% | -$519K |
|
367
Equitable Holdings
EQH
$13.3B
| $5.45M | 0.03% |
176,321
-14,948
| -8% | -$493K |
|
368
Heron Therapeutics
HRTX
$101M
| $5.45M | 0.03% |
952,087
+390,810
| +70% | +$2.86M |
|
369
Keysight
KEYS
$58.5B
| $5.45M | 0.03% |
34,473
-4,466
| -11% | -$744K |
|
|
MRTX
370
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.44M | 0.03% |
66,201
+27,070
| +69% | +$2.77M |
|
371
BioMarin Pharmaceuticals
BMRN
$11.7B
| $5.43M | 0.03% |
70,383
+8,266
| +13% | +$692K |
|
372
Novavax
NVAX
$1.25B
| $5.4M | 0.03% |
73,261
+41,601
| +131% | +$3.71M |
|
373
BioCryst Pharmaceuticals
BCRX
$2.27B
| $5.39M | 0.03% |
331,713
-120,924
| -27% | -$1.94M |
|
374
Ligand Pharmaceuticals
LGND
$5.99B
| $5.38M | 0.03% |
76,655
+17,932
| +31% | +$1.3M |
|
|
BHVN
375
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $5.34M | 0.03% |
45,001
-7,875
| -15% | -$982K |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Rafferty Asset Management held 1,372 positions worth $16.9B, down 11% from $19B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Rafferty Asset Management withdrew a net $1.02B in Q1 2022, closing 155 positions and reducing 680 holdings. Its most notable exit was Xilinx Inc, an estimated $169M position sold in full.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Financials and Energy.
Against the trend, Rafferty Asset Management opened a new position in Synaptics worth $33.9M.
- Rafferty Asset Management's largest Q1 2022 buy was Synaptics: 170,061 shares worth $33.9M.
- Rafferty Asset Management added most to Advanced Micro Devices in Q1 2022, an estimated $138M increase.
- Rafferty Asset Management's biggest Q1 2022 reduction was iShares Russell 2000 ETF, cutting an estimated $184M.
- Rafferty Asset Management fully exited Xilinx Inc in Q1 2022, selling an estimated $169M.
- Rafferty Asset Management's ten largest holdings make up 39% of its $16.9B portfolio in Q1 2022.
- Rafferty Asset Management opened 74 new positions and closed 155 in Q1 2022.
- Rafferty Asset Management's portfolio value fell 11% quarter-over-quarter to $16.9B.
Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.